Increase in right ventricular lead pacing threshold following stereotactic ablative therapy for ventricular tachycardia

Wijesuriya, Nadeev; Galante, Joao R; Sisodia, Caroline; Whitaker, John; Ahmad, Shahreen; Rinaldi, Christopher A.

doi:10.1016/j.hrcr.2023.05.011

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these reductions are relatively modest, patients currently referred for STAR are often amongst the sickest of arrhythmia patients, with the most intractable forms of VT, and co-morbidities which often prohibit catheter ablation. Reassuringly, only one cardiac implantable electrical device (CIED) adverse effect has been reported thus far, involving a rise in RV lead threshold with no further consequence ( 114 ), which is important given the vast majority of STAR referrals are for those with ICDs and CRT-Ds in situ . STAR is also being considered in the management of refractory AF, but concerns remain about the risk of atrio-oesophageal fistula, and it remains a relatively experimental treatment for this indication.…”

Section: Novel Directionsmentioning

confidence: 99%

Managing arrhythmia in cardiac resynchronisation therapy

de Vere,

Wijesuriya,

Elliott

et al. 2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Arrhythmia is an extremely common finding in patients receiving cardiac resynchronisation therapy (CRT). Despite this, in the majority of randomised trials testing CRT efficacy, patients with a recent history of arrhythmia were excluded. Most of our knowledge into the management of arrhythmia in CRT is therefore based on arrhythmia trials in the heart failure (HF) population, rather than from trials dedicated to the CRT population. However, unique to CRT patients is the aim to reach as close to 100% biventricular pacing (BVP) as possible, with HF outcomes greatly influenced by relatively small changes in pacing percentage. Thus, in comparison to the average HF patient, there is an even greater incentive for controlling arrhythmia, to achieve minimal interference with the effective delivery of BVP. In this review, we examine both atrial and ventricular arrhythmias, addressing their impact on CRT, and discuss the available evidence regarding optimal arrhythmia management in this patient group. We review pharmacological and procedural-based approaches, and lastly explore novel ways of harnessing device data to guide treatment of arrhythmia in CRT.

show abstract

Section: Novel Directionsmentioning

confidence: 99%